Table 1

Patients' characteristics and response to Hsp32/HO-1-targeted drugs

Patient no.SexAge, yCML phaseImatinib-resistantWBC, G/LHb g/dLPlt, G/LCytogeneticsBCR/ABL point mutationsIC50 SMA-ZnPPIC50 PEG-ZnPP
1M47BPYes30.410.6141t(9;22), i17, +8Glu279/Lys His396/Arg5n.t.
2F46CPNo38.811.9569t(9;22)wt10n.t.
3M49BPNo16.5812.2871t(9;22)wt15n.t.
4M59CPNo159.412.4168t(9;22)n.t.3n.t.
5F80CPNo17.113.7247t(9;22)n.t.n.t.2
6M67APYes49.514.1638t(9;22)Glu255Lysn.t.4
7M69APYes19.18.4132t(9;22)wtn.t.4
8F67CPNo27.913.2178t(9;22)wtn.t.10
9M18APNo3711.8114t(9;22), +8n.t.n.t.13
10M66BPYes3.47.5121t(9;22), i17, +8Val379Ilen.t.20
11M74CPNo13.78.7720t(9;22)wtn.t.6
12F58CPNo28.913.5347t(9;22)n.t.n.t.3
13M65BPYes96.111.366t(9;22)Thr315Ala Gly250Glu1510
14M30CPNo156.812.2171t(9;22)wtn.t.12
15M64CPNo3428.9478t(9;22)n.t.7n.t.
16F74CPNo103.510.5717t(9;22)n.t.5n.t.
17M19CPNo9614.6500t(9;22)n.t.618
18F45CPNo89.112.2536t(9;22)n.t.n.t.12
19M73APNo112.211.9394t(9;22), t(2;10)n.t.8n.t.
20M68CPNo190.012.3490t(9;22)n.t.8n.t.
21M67CPNo41.414.8310t(9;22)n.t.820
22M73CPYes21.113.7754t(9;22)Phe359Valn.t.12
23M67APYes16.29.969t(9;22)Met244Val68
  • CP indicates chronic phase; AP, accelerated phase; BP, blast phase; WBC, white blood cell count; Hb, hemoglobin; Plt, platelet count; wt, wild type BCR/ABL; and n.t., not tested.